ClinicalTrials.gg
CompletedNCT04470908Updated Oct 26, 2024Results posted

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

A Phase 1 interventional study of Zanubrutinib and Rifabutin in Healthy and Male, sponsored by BeiGene. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.

02

Conditions studied

  • Healthy
  • Male

Keywords

  • Phase 1
  • Healthy volunteers
  • Pharmacokinetics
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Males of any race, between 18 and 65 years of age, inclusive.
  2. Male participants in good health as determined by past medical history, physical examination, vital signs, and laboratory tests at screening
  3. Must have a (BMI) between 18 and 32 kg/m\^2

Key Exclusion Criteria:

  1. Participants with a history or presence of any clinically significant disease
  2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)
  3. History of drug or alcohol abuse within 1 year prior to check-in
  4. Use or intended use of any nonprescription medications/products including vitamins, minerals, herbal/plant-derived preparations within 7 days prior to check-in
  5. A positive surface antigen (HBsAg) or test result and/or a positive (HIV) at screening
  6. Use of tobacco- or nicotine-containing products within 3 months prior to check-in
  7. Use or intended use of any prescription medications/products within 14 days prior to check-in

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Zanubrutinib + Rifabutin

    Day 1: zanubrutinib Days 3 to 10: rifabutin Day 11: zanubrutinib and rifabutin

    Drug: Zanubrutinib · Drug: Rifabutin

Interventions

  • Single oral dose of 320 mg

    Also known as: BGB-3111, Brukinsa

  • Oral dose of 300 mg once daily

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  2. AUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  3. Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  4. Time to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  5. Time of the Last Quantifiable Concentration (Tlast) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  6. Apparent Terminal Elimination Half-life (t1/2) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  7. Apparent Oral Clearance (CL/F) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

  8. Apparent Volume of Distribution (Vz/F) of Zanubrutinib

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11

Secondary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    Adverse events (AEs) and serious adverse events included for summary, AEs that start during or after the first dose, or start prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters

    Time frame: From the date of first study drug administration to 30 days after last dose (up to 3.5 months)

07

Results

Posted Dec 14, 2023

Participant flow

This was a single-center study with dosing in a fixed sequence. A total of 13 participants were enrolled and 12 completed the study.

Zanubrutinib on Day 1
Participant flow — Zanubrutinib on Day 1
MilestoneZanubrutinib + Rifabutin
Started13
Completed13
Not completed0
Rifabutin on Days 3 to 10
Participant flow — Rifabutin on Days 3 to 10
MilestoneZanubrutinib + Rifabutin
Started13
Completed13
Not completed0
Zanubrutinib + Rifabutin on Day 11
Participant flow — Zanubrutinib + Rifabutin on Day 11
MilestoneZanubrutinib + Rifabutin
Started13
Completed12
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryArea Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib
h*ng/mLZanubrutinibZanubrutinib + Rifabutin
Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib2700 ± 24.81530 ± 21.4
Statistical analysis
  • Zanubrutinib vs Zanubrutinib + Rifabutin · Ratio of geometric least squares means: 0.566 · 90% CI 0.525 to 0.610
PrimaryAUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Geometric mean · h*ng/mL
AUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib
h*ng/mLZanubrutinibZanubrutinib + Rifabutin
AUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib2780 ± 23.31590 ± 22.2
Statistical analysis
  • Zanubrutinib vs Zanubrutinib + Rifabutin · Ratio of geometric least squares means: 0.560 · 90% CI 0.532 to 0.589
PrimaryMaximum Observed Plasma Concentration (Cmax) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib
ng/mLZanubrutinibZanubrutinib + Rifabutin
Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib489 ± 38.1253 ± 33.7
Statistical analysis
  • Zanubrutinib vs Zanubrutinib + Rifabutin · Ratio of geometric least squares means: 0.518 · 90% CI 0.441 to 0.608
PrimaryTime to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Median · Hours
Time to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
HoursZanubrutinibZanubrutinib + Rifabutin
Time to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib1.50 (1.00 to 4.02)2.00 (1.00 to 8.00)
PrimaryTime of the Last Quantifiable Concentration (Tlast) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Median · Hours
Time of the Last Quantifiable Concentration (Tlast) of Zanubrutinib
HoursZanubrutinibZanubrutinib + Rifabutin
Time of the Last Quantifiable Concentration (Tlast) of Zanubrutinib36.0 (24.0 to 36.0)36.0 (24.0 to 36.0)
PrimaryApparent Terminal Elimination Half-life (t1/2) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Mean · Hours
Apparent Terminal Elimination Half-life (t1/2) of Zanubrutinib
HoursZanubrutinibZanubrutinib + Rifabutin
Apparent Terminal Elimination Half-life (t1/2) of Zanubrutinib7.24 ± 3.107.00 ± 4.46
PrimaryApparent Oral Clearance (CL/F) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Geometric mean · Liters/hour
Apparent Oral Clearance (CL/F) of Zanubrutinib
Liters/hourZanubrutinibZanubrutinib + Rifabutin
Apparent Oral Clearance (CL/F) of Zanubrutinib115 ± 23.3201 ± 22.2
PrimaryApparent Volume of Distribution (Vz/F) of Zanubrutinib
Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of Zanubrutinib
LitersZanubrutinibZanubrutinib + Rifabutin
Apparent Volume of Distribution (Vz/F) of Zanubrutinib1080 ± 68.41750 ± 70.9
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

Adverse events (AEs) and serious adverse events included for summary, AEs that start during or after the first dose, or start prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters

Time frame:
From the date of first study drug administration to 30 days after last dose (up to 3.5 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsZanubrutinib on Day 1Rifabutin on Days 3 to 10Zanubrutinib + Rifabutin on Day 11
At least 1 treatment-emergent adverse event (TEAE)160
Serious adverse events000
Vital sign TEAEs000
Physical examination TEAEs000
Electrocardiogram TEAEs000
Laboratory-related TEAEs000

Adverse events

Collected over From the date of first study drug administration to 30 days after last dose (up to 3.5 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib on Day 10/13 (0%)0/13 (0%)1/13 (7.7%)
Rifabutin on Days 3 to 100/13 (0%)0/13 (0%)6/13 (46.2%)
Zanubrutinib + Rifabutin on Day 110/13 (0%)0/13 (0%)0/13 (0%)
Most frequent other events
Most frequent other events
EventZanubrutinib on Day 1Rifabutin on Days 3 to 10Zanubrutinib + Rifabutin on Day 11
ChromaturiaRenal and urinary disorders0/136/130/13
Vessel puncture site haematomaGeneral disorders1/130/130/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zanubrutinib + Rifabutin
Mean48.8 ± 11.00
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib + Rifabutin
Female0
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zanubrutinib + Rifabutin
Hispanic or Latino8
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zanubrutinib + Rifabutin
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Nov 2020, 3 months.

Results were first posted in Dec 2023, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 14, 2020
StartActual
Jul 29, 2020
Primary completionActual
Nov 10, 2020
CompletionActual
Nov 10, 2020
Results first posted
Dec 14, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04470908
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Jul 29, 2020
Primary completion
Nov 10, 2020
Completion
Nov 10, 2020
Results posted
Dec 14, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Rifabutin

Start the discussion